AKT1 and glioblastoma: Both free and PBS-encapsulated CBD similarlydecreased AKT Ser473 phosphorylation and increased LC3-II, confirmingthat nanoencapsulation preserves CBD’s signaling effects. Sun et al. developed GZCX (particles approximately200 nm), a dual receptor–mediated, BBB-permeable carrier coloadingGboxin, a drug that was designed to inhibit the process of oxidativephosphorylation in GBM cells, and CBD for GBM treatment.